期刊文献+

骨髓增生异常综合征患者血小板变化与血浆纤溶抑制物和蛋白Z的关系

下载PDF
导出
摘要 目的探讨初诊骨髓增生异常综合征(MDS)患者血小板变化与血浆凝血酶激活的纤溶抑制物(TAFI)和蛋白Z的关系。方法初诊原发性MDS患者78例,其中血小板减少59例,血小板正常19例。另取40例同期健康体检者为对照组。采用酶联免疫吸附法测定各组血浆TAFI和蛋白Z浓度。结果 MDS患者血小板减少、血小板正常及对照组血浆TAFI、蛋白Z浓度差异有统计学意义(P均<0.01)。MDS患者血小板减少组血浆TAFI水平与血小板计数呈负相关(r=-0.868,P<0.01),血浆蛋白Z水平与血小板计数呈正相关(r=0.924,P<0.01)。MDS患者血小板正常组及对照组血浆TAFI及蛋白Z水平与血小板计数无关。结论初诊MDS患者血小板计数减少时血浆TAFI和蛋白Z水平的变化是一种代偿性的改变,有利于减轻出血倾向。
出处 《山东医药》 CAS 北大核心 2011年第33期41-42,共2页 Shandong Medical Journal
  • 相关文献

参考文献6

二级参考文献39

  • 1Hong Ren,Ning Du,Gang Liu,Heng-Tong Hu,Wei Tian,Zhi-Ping Deng,Jing-Sen Shi.Analysis of variabilities of serum proteomic spectra in patients with gastric cancer before and after operation[J].World Journal of Gastroenterology,2006,12(17):2789-2792. 被引量:25
  • 2Pike RN, Buckle AM, le Bonniee BF, et al. Control of the coagulation system by serpins. Getting by with a litde help from glycosaminoglycans.FEBS J, 2005, 272(19):4842.
  • 3Broze GJ Jr, Miletich JP. Protein Z-dependent regulation of coagulation. Thromb Haemost, 2001, 86(1) :8.
  • 4Sayinalp N, Haznedaroglu IC, Buyukasik Y, et al. Protein C inhibitor and serum amyloid A in irnmtme thrombocytopaenic purpura. J Intern Med Res, 2004, 32(1): 62.
  • 5Jones PA, Baylin SB. The epigenomies of cancer [J]. Cell, 2007,128:683.
  • 6Silverman LR, Holland JF, Weinberg RS,et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastie syndromes [J]. Leukemia, 1993,7 (Suppl. 1) : 21.
  • 7Silverman LR, McKenzie DR, Peterson BL, et al. Response rates in patients with acute myeloid leukemia, treated with azacytidine, using WHO and intenrational working group criteria for myelodysplastic syndrome [J]. Blood, 2005,106 : 525a.
  • 8Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B [J]. J Clin Oncol, 2002,20 : 2429.
  • 9Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421,8921, and 9221 by the Cancer and Leukemia Group B [J]. J Clin Oncol, 2006, 24:2895.
  • 10Fenaux P, Mufti G, Santini V, et al. Azacitidine treatment prolongs overall survival in higher risk MDS paticats compared with conventional care regimens: results of the AZA-001 phase III study [J]. Blood, 2007,110:250a.

共引文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部